Minimal change nephropathy/focal segmental glomerulosclerosis
Conditions
Interventions
rituximab group:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients who were diagnosed with MCD/FSGS (MN) by renal biopsy in the outpatient/inpatient department of nephrology of West China Hospital of Sichuan University from May 1, 2025 were included; 2. Patients over 18 years old, regardless of gender or race; 3. Patients with regular follow-up.
Exclusion criteria
Exclusion criteria: 1.Patients with MCD/FSGS caused by secondary causes; known malignant disease; positive double-stranded DNA antibody; currently treated with penicillamine, non-steroidal anti-inflammatory drugs, cytotoxic drugs or cyclosporine; treated with corticosteroids for more than 3 months in the previous two years; pregnant or contraceptive; or previous adverse reactions to prednisolone and methylprednisolone; 2. patients who cannot be followed up regularly.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| creatinine;Estimate glomerular filtration rate;urea;Uric Acid;urinalysis;Urine protein-creatinine ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| .Blood routine examination;ANA and antinuclear antibody profile;Complement C3;Complement C4;PLA2R; | — |
Countries
China
Contacts
Public ContactQin Wei
West China Hospital of Sichuan University
Outcome results
None listed